

**PRODUCT INFORMATION**

<b>Common Name</b>	IMMU-132, hRS7-SN-38, hRS7-SN-38-ADC, hRS7-[CL-SN-38], hrS7-SN-38
<b>Synonyms</b>	TACSTD2;GA733-1;M1S1;TROP2
<b>Applications</b>	ELISA; Flow Cyt
<b>Recommended Dilutions</b>	ELISA 1:5000-10000; Flow Cyt 1:100
<b>Formulation &amp; Reconstitution</b>	Lyophilized from sterile PBS, pH 7.4. Normally 5% - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution.
<b>Host Species</b>	Humanized
<b>IgG type</b>	IgG1
<b>Reactivity</b>	Human
<b>Target</b>	Trop2
<b>Uniprot ID</b>	P09758
<b>Description</b>	Anti-Trop2 (sacituzumab biosimilar) mAb
<b>Delivery</b>	In Stock
<b>Storage &amp; Shipping</b>	Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.
<b>Background</b>	Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.
<b>Usage</b>	Research use only
<b>Conjugate</b>	Unconjugated

CONFIDENTIAL



## Anti-Trop2 (sacituzumab govitecan biosimilar) mAb ELISA

0.2  $\mu$ g of Trop2, mFc-His Tagged protein per well




Figure 1. ELISA plate pre-coated by 2  $\mu$ g/ml (100  $\mu$ l/well) Human Trop2, mFc-His tagged protein PME100501 can bind Anti-Trop2 Neutralizing antibody in a linear range of 0.13-16.0 ng/ml.




Figure 2. Flow cytometry analysis of antigen binding of anti-human Trop2 mAb(BME100023).

(A) BME100023 does not bind to 293T cells that do not express Trop2.

(B) A clear peak shift of BME100023 was seen compared to the control when incubated with Trop2-expressing A431 cells, indicating strong binding of BME100023 to Trop2. Antibodies were incubated at 2  $\mu$ g/mL.






Figure 3. HEK293 cell line transfected with irrelevant protein (B) and human Trop2 protein (A) were surface stained with anti-Trop2 neutralizing antibody  $1\mu\text{g/ml}$  (sacituzumab) followed by Alexa 488-conjugated anti-human IgG secondary antibody.

DIMABIO CONFIDENTIAL

